Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
This trial was a Phase I/II, non-randomized, open label, multi-center study, following a sequential 2- part design. The first part, Phase I, was designed to assess whether there is a pharmacokinetic interaction between Glivec/Gleevec (imatinib) and RAD001(everolimus) as well as to collect safety data when these two drugs are co-administered. The second part, (Phase II), was designed to assess the potential efficacy of the combination in imatinib-resistant GIST patients in two strata of patients:
- Patients resistant to imatinib as first-line drug therapy and in whom the maximum tolerated dose was at least 600 mg/d (Stratum 1, first-line resistant/refractory)
- Patients resistant to imatinib as well as to post-imatinib drug therapy (Stratum 2, post second-line therapy).
Condition | Intervention | Phase |
---|---|---|
Gastrointestinal Stromal Tumors |
Drug: Everolimus + Imatinib |
Phase 1 Phase 2 |
Study Type: | Interventional |
Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | A Phase I-II, Open-label Study of RAD001 in Combination With Glivec®/Gleevec™ (Imatinib) in Patients With Glivec/Gleevec-refractory/Resistant Gastrointestinal Stromal Tumors. |
- assess the safety and tolerability of the combination administration of RAD001 and imatinib when given to patients with imatinib-refractory gastro-intestinal stromal tumors (GIST). [ Designated as safety issue: No ]
- assess the pharmacokinetics of the combination administration of RAD001 and imatinib in this patient population. [ Designated as safety issue: No ]
- assess clinical efficacy of the combination regimen in this patient population. [ Designated as safety issue: No ]
- assess mTOR pathway activity before treatment, and inhibition of mTOR pathway activity during treatment as a predictive factor of response, as shown by molecular pathological examination of the tumor. [ Designated as safety issue: No ]
- assess the relationship between drug-induced changes in the principal molecular marker of intratumoral mTOR activity and changes in other molecular markers of tumoral activity (e.g. indicators of pathway activity, cell proliferation and apoptosis). [ Designated as safety issue: No ]
- assess the relationship between drug-induced changes in tumoral metabolism, as shown by functional imaging with 18F-fluorodeoxyglucose positron emission tomography (FDC-PET), with clinical outcome and changes in molecular pathology. [ Designated as safety issue: No ]
Enrollment: | 120 |
Study Start Date: | November 2002 |
Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: RAD001 + Glivec | Drug: Everolimus + Imatinib |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Phase l:
- Patients aged ≥ 18 years
- Patients with a histologically proven diagnosis of GIST and clinical evidence of resistance to imatinib despite at least 4 months continuous treatment with imatinib
- Patients with at least 2 months at a dosage of ≥ 600 mg/day (progression despite uninterrupted therapy for 2 months at ≥800 mg/d for patients entering the Phase I cohort investigating the 800 mg/d dose)
- Patients were to have at least one measurable lesion (longest diameter ≥20 mm on conventional CT or MRI scan
- patients were to have ≥10 mm on spiral CT) and were to have a WHO Performance Status Score ≤ 2.
- Patients also were to have adequate bone marrow, liver and renal function on imatinib treatment, as specified in the protocol
Phase ll:
• For Phase II (Stratum 2) patients must have progression on other 2nd line drug therapies following prior progression on imatinib (Stratum 2)
Exclusion Criteria:
- Women who are pregnant or breast-feeding
- Patients presenting with known or symptomatic CNS metastases or leptomeningeal involvement
- Patients with any concurrent major medical condition liable to compromise the patient's participation in the study (e.g. known HIV infection, uncontrolled diabetes, serious cardiac dysrhythmia or condition, New York Heart Association classification of III or IV, congestive cardiac failure, myocardial infarction with 6 months, unstable angina, chronic or acute renal or liver disease, uncontrolled infections including abscess or fistulae, etc.)
- Patients with a history of another malignancy within 5 years prior to study entry, except curatively treated non-melanotic skin cancer or in-situ cervical cancer
- Patients unwilling to or unable to comply with the protocol
- Patients who are receiving glucocorticoids (only if the p70s6 kinase1 assay is being performed), since these have been shown to inhibit p70s6 kinase1 activity.
Other protocol-defined inclusion/exclusion criteria may apply
United States, Massachusetts | |
Dana Faber Cancer Institute | |
Boston, Massachusetts, United States, 02115 | |
United States, New York | |
College of Physicians & Surgeons of Columbia University | |
New York, New York, United States, 10032 | |
United States, Pennsylvania | |
Chase Cancer Center | |
Philadelphia, Pennsylvania, United States, 19111-2497 | |
Belgium | |
Novarts Investigative Site | |
Edegem, Belgium, 2650 | |
Novarts Investigative Site | |
Leuven, Belgium, 3000 | |
France | |
Novartis Investigative Site | |
Bordeaux Cedex, France, 33076 | |
Novartis Investigative Site | |
Lille Cedex, France, 59020 | |
Novartis Investigative Site | |
Lyon Cedex 08, France, 69373 | |
Novartis Investigative Site | |
Marseille, France, 13005 | |
Novartis Investigative Site | |
Villejuif, France, 94805 | |
Germany | |
Novartis Investigative Site | |
Berlin, Germany, 13125 | |
Novartis Investigative Site | |
Frankfurt, Germany, 60488 | |
Novartis Investigative Site | |
Hamburg, Germany, 20246 | |
Novartis Investigative Site | |
Koln, Germany, 50973 | |
Novartis Investigative Site | |
Muenchen, Germany, 81377 | |
Novartis Investigative Site | |
Tubingen, Germany, 72076 |
Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
No publications provided
Responsible Party: | Novartis ( Novartis Pharmaceuticals ) |
ClinicalTrials.gov Identifier: | NCT01275222 History of Changes |
Other Study ID Numbers: | CRAD001C2206 |
Study First Received: | January 10, 2011 |
Last Updated: | May 31, 2012 |
Health Authority: | United States: Food and Drug Administration Belgium: Belgium Health Authorities France: afssaps Germany:BfArM |
Keywords provided by Novartis:
GIST everolimus mTOR Imatinib resistant Imatinib-refractory/resistant gastrointestinal stromal tumors |
Additional relevant MeSH terms:
Gastrointestinal Stromal Tumors Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Everolimus Sirolimus Imatinib Immunosuppressive Agents Immunologic Factors |
Physiological Effects of Drugs Pharmacologic Actions Antibiotics, Antineoplastic Antineoplastic Agents Therapeutic Uses Antifungal Agents Anti-Infective Agents Anti-Bacterial Agents Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on October 18, 2012